Replimune Group (NASDAQ:REPL) Director Joseph Slattery Sells 5,200 Shares of Company Stock

Replimune Group, Inc. (NASDAQ:REPL) Director Joseph Slattery sold 5,200 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $21.80, for a total transaction of $113,360.00. Following the transaction, the director owned 1,467 shares in the company, valued at $31,980.60. The trade was a 78.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Replimune Group Trading Up 4.6%

REPL traded up $1.02 during trading on Tuesday, reaching $23.28. 3,017,307 shares of the company’s stock were exchanged, compared to its average volume of 4,324,637. The company’s fifty day moving average price is $14.23 and its 200-day moving average price is $9.75. The firm has a market capitalization of $2.21 billion, a PE ratio of -8.34 and a beta of 0.93. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $23.41. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.24. As a group, equities analysts forecast that Replimune Group, Inc. will post -2.40 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Replimune Group during the 2nd quarter worth approximately $99,171,000. Montanova Capital LLC raised its stake in shares of Replimune Group by 4.0% during the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after acquiring an additional 168,000 shares during the last quarter. Opaleye Management Inc. acquired a new position in shares of Replimune Group during the second quarter worth $15,332,000. Dimensional Fund Advisors LP lifted its holdings in shares of Replimune Group by 1.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock worth $8,719,000 after purchasing an additional 20,742 shares during the period. Finally, EcoR1 Capital LLC bought a new stake in shares of Replimune Group in the first quarter worth $7,650,000. 92.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on REPL. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Wolfe Research raised Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Replimune Group in a research report on Wednesday, November 4th. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a research note on Friday, August 7th. Finally, Wall Street Zen upgraded Replimune Group from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.33.

Replimune Group Company Profile

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.